| Characteristics | Patients (n=66) |
ITLpos at week 54 (n=41) |
ITLneg at week 54 (n=25) |
p |
|---|---|---|---|---|
| Age, years* | 56 (47-68) | 59 | 51 (42-65) | <0.05 |
| Body mass index* | 24 (22-27) | 24 (22-27) | 23(20-28) | 0.2 |
| Female** | 57 (86%) | 35 (85%) | 22 (88%) | 1 |
| Disease duration, years* | 14 (9-18) | 16 (10-19) | 12 (5-16) | 0.1 |
| Rheumatoid factor** | 54 (82%) | 33(80%) | 22(96.6%) | 0.3 |
| ACPA** | 54 (82%) | 32(82%) | 22(88%) | 0.2 |
| DAS28 at baseline*** | 5.5 (1.3) | 5.3 (1.1) | 5.8 (1.4) | 0.06 |
| CRP at baseline*** | 18 (19) | 15 (17) | 23 (20) | 0.05 |
| Concomitant treatment: | ||||
| Methotrexate** | 43 (65%) | 32 (78%) | 11 (44%) | <0.01 |
| Methotrexate dose, mg/week* | 15.6 (5.5) | 12.2 (8.5) | 8.8 (7.4) | 0.1 |
| Others DMARDs ** | 16 (24%) | 7 (17%) | 9 (36%) | 0.6 |
| Prednisone** | 43 (65%) | 31 (75%) | 12 (48%) | <0.05 |
| Monotherapy ** | 8 (12%) | 5 (12%) | 3(15%) | 1 |